Please assess the completion status of the following clinical trial:

Trial Title: DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent, including authorization to release health information~* Skeletally mature, male or female patients 18 to 65 years of age with diagnosis of plantar fasciitis~* Persistent heel pain for more than three months~* Women of child bearing potential must have a negative urine pregnancy test (UPT) at Screening Visit and must use an effective method of birth control during the course of the study~Exclusion Criteria:~* Previous surgery on the midfoot or hindfoot~* Neuromuscular disease~* Systemic muscle weakness~* Planning a pregnancy during the study~* Current enrollment in an investigational drug or device study or participation in such a study within the last 30 days prior to first visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- DAXI 240 U (Type: EXPERIMENTAL): DaxibotulinumtoxinA for injection for the treatment of plantar fasciitis (PF) with 240 U
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Intramuscular injection

Based on this trial design, predict the completion outcome and termination type (if applicable).